|
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. |
|
|
Stock and Other Ownership Interests - MolecularMD |
|
Consulting or Advisory Role - Blueprint Medicines; Deciphera; MolecularMD; Novartis |
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst) |
Expert Testimony - Novartis |
|
|
Stock and Other Ownership Interests - Abbott Laboratories; Allergan (I) |
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi Sankyo; deciphera; Lilly; MORE Health; Research to Practice; UpToDate |
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - UptoDate |
|
Other Relationship - Research to Practice |
|
|
Stock and Other Ownership Interests - Aimmune; Alnylam; Biomarin; Bluebird Bio; Cochlear; CSL Limited; Dova Pharmaceuticals; GW Pharmaceuticals; Juno Therapeutics; Kiadis Pharma; Kite, a Gilead company; Sage Therapeutics; TherapeuticsMD; Vertex |
Honoraria - Gilead Sciences; Halozyme; Merck Serono; pfizer; Specialised Therapeutics; Targovax |
Consulting or Advisory Role - Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Pfizer; Sirtex Medical; Targovax |
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Specialised Therapeutics (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme |
|
|
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar |
Consulting or Advisory Role - ADC Therapeutics; Bayer; Blueprint Medicines; Daiichi Sankyo; Deciphera; Exelixis; Janssen-Cilag; Janssen-Cilag; Lilly; Nanobiotix |
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis |
Travel, Accommodations, Expenses - Pharmamar |
|
|
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst) |
|
|
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Deciphera |
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera; Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst) |
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Novartis (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - Ipsen (Inst); MSD (Inst) |
|
|
|
Consulting or Advisory Role - Blueprint Medicines; Deciphera |
Speakers' Bureau - Blueprint Medicines |
Research Funding - Bayer; Deciphera; Pfizer |
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar |
|
|
No Relationships to Disclose |
|
|
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - Immune Design |
|
|
Consulting or Advisory Role - Blueprint Medicines; Epizyme; Janssen; Lilly |
Speakers' Bureau - Janssen Oncology; Lilly |
|
|
Consulting or Advisory Role - Deciphera; Exelixis; Merck (I) |
Research Funding - Array BioPharma (Inst); Deciphera (Inst) |
|
|
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar |
Consulting or Advisory Role - Bayer; Clinigen Group; Deciphera; Lilly; Novartis; Pfizer; PharmaMar; Roche |
Research Funding - Novartis (Inst) |
|
|
|
Stock and Other Ownership Interests - Deciphera |
Travel, Accommodations, Expenses - Deciphera |
|
|
|
Stock and Other Ownership Interests - Deciphera |
Travel, Accommodations, Expenses - Deciphera |
|
|
|
Stock and Other Ownership Interests - Deciphera; Immunogen |
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties |
|
|
|
Consulting or Advisory Role - deciphera; Exelixis |
Research Funding - ADCO (Inst); Arog (Inst); ArQule; Blueprint Medicines (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Lilly (Inst); Novartis (Inst); Springworks Therapeutics (Inst) |
Travel, Accommodations, Expenses - Deciphera; Deciphera; NCCN |
Other Relationship - NCCN |
|
|
Leadership - Innate Pharma |
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; PharmaMar; Roche |
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Pharmamar; Roche |
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |